At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06160 BEONE MEDICINES
Market Closed 10-02 16:08:09
212.200
-13.200
-5.86%
High212.800Low208.400Vol3.05M
Open212.600D1 Closing225.400Amplitude1.95%
Mkt Cap327.21BTradable Cap302.81BTotal Shares1.54B
T/O646.39MT/O Rate0.21%Tradable Shares1.43B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BEONE MEDICINES: JPMorgan Chase & Co. Acquires Shares, Long Position Rises to 10.05%
HK Disclosure  ·  10-02 17:43
BEONE MEDICINES: JPMorgan Chase & Co. Acquires Shares, Long Position Rises to 10.05%
Movement Alert｜BEONE MEDICINES Drops 6.3% in Regular Trading, Trading at 209.6 HKD
Market Focus  ·  10-02 09:36
Movement Alert｜BEONE MEDICINES Drops 6.3% in Regular Trading, Trading at 209.6 HKD
Movement Alert｜BEONE MEDICINES Rises 3.03% in Regular Trading, Global Asset Manager Capital Group Continues Large-Scale Accumulation
Market Focus  ·  09-30 10:05
Movement Alert｜BEONE MEDICINES Rises 3.03% in Regular Trading, Global Asset Manager Capital Group Continues Large-Scale Accumulation
BeOne Medicines: The Capital Group Companies, Inc. Acquires Shares
HK Disclosure  ·  09-28
BeOne Medicines: The Capital Group Companies, Inc. Acquires Shares
Hong Kong Stocks Open Mixed: Hang Seng Edges Down 0.09%, Tech Index Flat, Memory Chip Plays Surge
Deep News  ·  09-23
Hong Kong Stocks Open Mixed: Hang Seng Edges Down 0.09%, Tech Index Flat, Memory Chip Plays Surge
Movement Alert｜BEONE MEDICINES Rises 3.01% in Regular Trading, Biotech Sector Rallies on Global Value Realization Thesis
Market Focus  ·  09-21
Movement Alert｜BEONE MEDICINES Rises 3.01% in Regular Trading, Biotech Sector Rallies on Global Value Realization Thesis
Movement Alert｜BEONE MEDICINES Falls 3.2% in Regular Trading, Biotech Sector Broadly Weak Amid Recent Director Share Sale
Market Focus  ·  09-16
Movement Alert｜BEONE MEDICINES Falls 3.2% in Regular Trading, Biotech Sector Broadly Weak Amid Recent Director Share Sale
Hong Kong Stocks Recover as WCLC Conference Sparks Biotech Rally, While US AI Slowdown Calls Raise Questions
Stock News  ·  09-14
Hong Kong Stocks Recover as WCLC Conference Sparks Biotech Rally, While US AI Slowdown Calls Raise Questions
BeOne Medicines Updates 2018 ESPP: 62,473 ADSs Purchased by 4,590 Employees
Bulletin Express  ·  09-14
BeOne Medicines Updates 2018 ESPP: 62,473 ADSs Purchased by 4,590 Employees
Movement Alert｜BEONE MEDICINES Rises 3.01% in Regular Trading, Global Asset Manager Capital Group Adds Major Stake Worth $1.07 Billion
Market Focus  ·  09-14
Movement Alert｜BEONE MEDICINES Rises 3.01% in Regular Trading, Global Asset Manager Capital Group Adds Major Stake Worth $1.07 Billion
BEONE MEDICINES: The Capital Group Companies, Inc. Acquires Shares
HK Disclosure  ·  09-11
BEONE MEDICINES: The Capital Group Companies, Inc. Acquires Shares
BeOne Medicines Shifts to Fully Electronic Distribution of Corporate Communications
Bulletin Express  ·  09-10
BeOne Medicines Shifts to Fully Electronic Distribution of Corporate Communications
BeOne Medicines 2026 Interim: Revenue Up 32.3% to USD 3.22 Billion, Net Income Surges to USD 464 Million
Bulletin Express  ·  09-10
BeOne Medicines 2026 Interim: Revenue Up 32.3% to USD 3.22 Billion, Net Income Surges to USD 464 Million
BeOne Medicines Issues Reminder on Shift to Electronic Distribution of Shareholder Materials
Bulletin Express  ·  09-10
BeOne Medicines Issues Reminder on Shift to Electronic Distribution of Shareholder Materials
BeOne Medicines Opens New Six-Month Offering for 2018 Employee Share Purchase Plan
Bulletin Express  ·  09-09
BeOne Medicines Opens New Six-Month Offering for 2018 Employee Share Purchase Plan
Movement Alert｜BEONE MEDICINES Falls 3.01% in Regular Trading, Market Still Digesting US Medicaid Drug Pricing Agreement
Market Focus  ·  09-09
Movement Alert｜BEONE MEDICINES Falls 3.01% in Regular Trading, Market Still Digesting US Medicaid Drug Pricing Agreement
Movement Alert｜BEONE MEDICINES Falls 3.07% in Regular Trading, Market Still Digesting US Medicaid Drug Pricing Agreement Impact
Market Focus  ·  09-08
Movement Alert｜BEONE MEDICINES Falls 3.07% in Regular Trading, Market Still Digesting US Medicaid Drug Pricing Agreement Impact
Movement Alert｜BEONE MEDICINES Declines 3.08% in Regular Trading, Trading at HK$214.2
Market Focus  ·  09-07
Movement Alert｜BEONE MEDICINES Declines 3.08% in Regular Trading, Trading at HK$214.2
UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts
Stock News  ·  09-07
UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts
Brokerage Adds Tencent and Innovent Bio to Buy List While Maintaining Positive Outlook on Tech and Hardware Sectors
Stock News  ·  09-04
Brokerage Adds Tencent and Innovent Bio to Buy List While Maintaining Positive Outlook on Tech and Hardware Sectors

Introduction

Company Name.
BEONE MEDICINES
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Issue price:
--